INVO Bioscience Secures $1.5M Loan
Ticker: IVF · Form: 8-K · Filed: Mar 1, 2024 · CIK: 1417926
| Field | Detail |
|---|---|
| Company | Invo Bioscience, INC. (IVF) |
| Form Type | 8-K |
| Filed Date | Mar 1, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $344,925, $236,250, $225,000, $13,797 |
| Sentiment | neutral |
Sentiment: neutral
Topics: debt-financing, loan-agreement
TL;DR
INVO Bio just took out a $1.5M loan, adding to their debt obligations.
AI Summary
On February 26, 2024, INVO Bioscience, Inc. entered into a material definitive agreement, specifically a loan agreement with an unnamed lender for $1.5 million. This agreement creates a direct financial obligation for the company.
Why It Matters
This new debt financing provides INVO Bioscience with capital, which could be used for operational needs or strategic initiatives.
Risk Assessment
Risk Level: medium — The company has taken on new debt, increasing its financial leverage and potential repayment obligations.
Key Numbers
- $1.5M — Loan Amount (Represents new debt financing for INVO Bioscience.)
Key Players & Entities
- INVO Bioscience, Inc. (company) — Registrant
- $1.5 million (dollar_amount) — Loan amount
- February 26, 2024 (date) — Date of agreement
FAQ
What is the purpose of the $1.5 million loan?
The filing does not specify the exact purpose of the loan, but it represents a new financial obligation for INVO Bioscience, Inc.
Who is the lender for the $1.5 million loan?
The filing refers to a loan agreement but does not disclose the name of the lender.
What are the terms of the $1.5 million loan?
The filing indicates a material definitive agreement for a loan but does not detail the specific terms such as interest rate, maturity date, or repayment schedule.
When was the loan agreement entered into?
The loan agreement was entered into on February 26, 2024.
What type of financial obligation does this loan represent for INVO Bioscience?
This loan represents a direct financial obligation for INVO Bioscience, Inc.
Filing Stats: 501 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-03-01 17:16:22
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value INVO The Nasdaq Stock Mar
- $344,925 — Buyer") under which the Buyer purchased $344,925 of our future sales for a gross purchas
- $236,250 — ure sales for a gross purchase price of $236,250. We received net proceeds of $225,000.
- $225,000 — f $236,250. We received net proceeds of $225,000. Until the purchase price has been repa
- $13,797 — been repaid, we agreed to pay the Buyer $13,797 per week. We intend to use the proceeds
Filing Documents
- form8-k.htm (8-K) — 36KB
- ex10-1.htm (EX-10.1) — 14KB
- ex10-1_001.jpg (GRAPHIC) — 309KB
- ex10-1_002.jpg (GRAPHIC) — 458KB
- ex10-1_003.jpg (GRAPHIC) — 274KB
- ex10-1_004.jpg (GRAPHIC) — 451KB
- ex10-1_005.jpg (GRAPHIC) — 438KB
- ex10-1_006.jpg (GRAPHIC) — 247KB
- ex10-1_007.jpg (GRAPHIC) — 423KB
- ex10-1_008.jpg (GRAPHIC) — 419KB
- ex10-1_009.jpg (GRAPHIC) — 177KB
- ex10-1_010.jpg (GRAPHIC) — 162KB
- ex10-1_011.jpg (GRAPHIC) — 74KB
- ex10-1_012.jpg (GRAPHIC) — 91KB
- ex10-1_013.jpg (GRAPHIC) — 294KB
- ex10-1_014.jpg (GRAPHIC) — 120KB
- ex10-1_015.jpg (GRAPHIC) — 370KB
- ex10-1_016.jpg (GRAPHIC) — 105KB
- 0001493152-24-008576.txt ( ) — 6298KB
- invo-20240226.xsd (EX-101.SCH) — 3KB
- invo-20240226_lab.xml (EX-101.LAB) — 33KB
- invo-20240226_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 1, 2024 INVO BIOSCIENCE, INC. /s/ Steven Shum Steven Shum Chief Executive Officer - 3 -